SciSparc (SPRC) closes TSXV acquisition, transfers pharma portfolio

SciSparc Ltd. (SPRC) reported it has closed the acquisition of a publicly traded company on the TSX Venture Exchange and transferred its advanced clinical‑stage pharmaceutical portfolio to that company.

Accepted by SEC EDGAR 10/27/2025 - 07:52 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

SciSparc Ltd. (SPRC) reported it has closed the acquisition of a publicly traded company on the TSX Venture Exchange and transferred its advanced clinical‑stage pharmaceutical portfolio to that company. The announcement was furnished via a Form 6-K that also includes the related press release as an exhibit.

The Form 6-K is incorporated by reference into SciSparc’s effective registration statements on Forms F-3 and S-8, aligning the disclosure with its existing U.S. registration frameworks.

Insights

Capital markets analyst

Administrative disclosure of a completed TSXV acquisition; neutral.

SciSparc states the acquisition of a publicly traded TSXV company has closed and that its advanced clinical-stage pharmaceutical portfolio was transferred to that entity. The disclosure is delivered via Form 6-K with an accompanying press release.

The filing also notes that this 6-K is incorporated by reference into existing F-3 and S-8 registration statements, a standard cross-referencing step that maintains consistency across U.S. disclosures. Cash consideration, valuation, and post-deal structure are not detailed in the excerpt.

A concrete milestone cited is the press release issued on October 24, 2025. Any operational or financial effects would depend on terms not included here; subsequent filings may provide specifics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SciSparc (SPRC) announce in its Form 6-K?

SciSparc announced the closing of an acquisition of a publicly traded TSXV company and the transfer of its advanced clinical-stage pharmaceutical portfolio to that company.

Which exchange is involved in the transaction disclosed by SPRC?

The acquired company is publicly traded on the TSX Venture Exchange (TSXV).

What assets did SciSparc say were transferred as part of the transaction?

SciSparc reported transferring its advanced clinical-stage pharmaceutical portfolio to the TSXV-traded company.

Where can I find more details about SciSparc’s announcement?

A press release titled “SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio” is furnished as Exhibit 99.1.

When did SciSparc issue the related press release?

The company issued the press release on October 24, 2025.

Is the 6-K integrated with SciSparc’s U.S. registration statements?

Yes. The 6-K is incorporated by reference into SciSparc’s registration statements on Forms F-3 and S-8.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2025 (Report No. 5)

Commission File Number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

On October 24, 2025, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-233417, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release issued by SciSparc Ltd. titled “SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SciSparc Ltd.
Date: October 27, 2025	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

3